Kumquat Biosciences Inc. has described heterocyclic compounds and PROTACs acting as GTPase KRAS (G12D, G12C, G12S and G13D mutant), and/or G12V and wild-type GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Shanghai Zhigen Pharmaceutical Technology Co Ltd. has divulged nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation and autoimmune diseases.
Shanghaitech University has identified G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of schizophrenia, among others.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized mast/stem cell growth factor receptor Kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory and neurological disorders.
Ikena Oncology Inc. has disclosed mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.
Obesity is a chronic disease caused by the concurrence of genetics and environmental and individual behaviors that lead to an imbalance between caloric intake and expenditure and are linked to increased mortality and morbidity.
The development of new antimicrobials to combat bacterial resistance is an urgent need given the increasing presence of multidrug-resistant organisms, an important concern especially for vulnerable individuals.
Synthetic, multi-epitope peptide vaccines are becoming an attractive universal influenza vaccine strategy. Longhorn Vaccines & Diagnostics LLC has created LHNVD-105, an influenza vaccine candidate consisting of unconjugated multi-epitope influenza peptides.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding $1.75 million to the University of Melbourne at the Peter Doherty Institute for Infection and Immunity to develop an oral therapeutic that restores the activity of common antibiotics used to treat community-acquired bacterial pneumonia (CABP).
Redhill Biopharma Ltd. has announced a survival benefit with its oral sphingosine kinase-2 (SPHK2) selective inhibitor opaganib (ABC-294640) in an in vivo Ebola virus study.
RSS
